Prosecution Insights
Last updated: October 01, 2026

Examiner: LOCKARD, JON MCCLELLAND

Tech Center 1600 • Art Units: 1647

This examiner grants 75% of resolved cases

Analysis

Jon McClelland Lockard has a portfolio of 854 resolved cases in Tech Center 1600. Within Art Unit 1647, the examiner maintains an allowance rate of 74.6 percent. The median days to allowance is 897, which indicates the timeline for reaching a final disposition. Practitioners can use this 897-day figure to manage expectations for prosecution speed. The 74.6 percent rate provides a baseline for the probability of securing a grant.

The interview lift of 27.2 percent suggests that verbal communication is a tool for increasing the 74.6 percent baseline allowance rate. This lift indicates that interviews are associated with a higher frequency of success. The 854 resolved cases provide a robust statistical foundation for these metrics. Practitioners should consider the 27.2 percent lift when planning their strategy for Art Unit 1647. The 897-day median pendency is a key factor in deciding the timing of such engagements.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

74.6%
Allow Rate
+14.6% vs TC avg
876
Total Applications
+27.2%
Interview Lift
897
Avg Prosecution Days
Based on 854 resolved cases, 2023–2026

Rejection Statute Breakdown

5.9%
§101 Eligibility
12.7%
§102 Novelty
8.0%
§103 Obviousness
51.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18199007 Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody Final Rejection Janssen Biotech, Inc.
18367444 AN AQUEOUS PHARMACEUTICAL FORMULATION INCLUDING A VEGF RECEPTOR FUSION PROTEIN Non-Final OA Regeneron Pharmaceuticals, Inc.
18037482 IMMUNO-ONCOLOGY TARGETS TO IMPROVE T-CELL METABOLIC RESPONSE Non-Final OA The Johns Hopkins University
18685045 CELL-SURFACE ANTIBODY TO A SPECIFIC BIOMARKER OF PANCREATIC BETA-CELLS Non-Final OA THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
18156442 COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month